Tag: BioE3 Policy

The Structural Insolvency of Synthetic Platforms

Why Ginkgo’s $930 Million Revenue Gap Forced a Pivot to Vertical Product R&D

8 Min Read

Stop Renting Biology: The Mandatory Pivot to Proprietary Asset Ownership

Synthetic Biology Business Models: Transitioning From Platform Foundries to Asset Creation

8 Min Read

The Asset Sovereignty Mandate: Why ‘Horizontal’ Synbio Platforms Are Starving in 2026

Synthetic Biology Business Models: Replacing Horizontal Foundries with Asset Sovereignty

6 Min Read